Risk of Positive Doping Tests Following Ingestion of Supplements Contaminated With Trace Quantities of Nandrolone Metabolites
NCT00682123 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2008-05-22
Summary
There is compelling evidence that some dietary supplements consumed by the general population are manufactured and stored under conditions that lead to contamination of the end product with small amounts of extraneous materials. In most cases, this is harmless, but for athletes liable to drug testing as a consequence of their participation in sport, the potential consequences of even trivial amounts of a prohibited substance may be catastrophic. Quality control procedures for pharmaceutical products normally specify the absence of contaminants at a level of more than 0.1%, ie 1mg/g. However, in the case of an anabolic steroid such as nandrolone, the amount that will cause a positive test has been estimated to be about 1-3µg (Geyer et al, 2004). In the case of a supplement that is taken in high doses (20-30 g/d), such as for example creatine, this means that a contamination level of something closer to 0.00001% (ie 1µg/g) may cause a positive test. This work have been supported by recent findings from our laboratory (Judkins et al, 2006). These data demonstrate that as little as 10μg of 19-noradrostenedione (19-NorAD) added to a creatine supplement resulted in a positive doping test in all volunteers testing. This is one thousand times less that the purity level specified for pharmaceutical agents and at this level, these contaminants are without any pharmacological action.
Proposals are under development to regulate the sale of dietary supplements for use by athletes to avoid accidental doping positives as a result of ingestion of contaminated supplements. This requires a knowledge of the amounts of contaminant that is likely to cause problems. The aim of the present study was to examine the urinary excretion pattern of nandrolone metabolites following 1µg, 2.5µg and 5µg doses of 19-norandrostendione in both male and female subjects. The quantity of 19-norandrostenedione administered in this study is representative of the amount previously reported as an undeclared contaminant in some dietary supplements. Given the speculation surrounding positive doping cases being attributed to ingestion of sports supplements contaminated with pro-hormones, this presents an important consideration for both athletes and doping agencies, as well as supplement manufacturers.
Conditions
- Positive Doping Tests in Sports
Interventions
- DIETARY_SUPPLEMENT
-
19-norandrostendione
Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner. The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects.
Sponsors & Collaborators
-
UK Sport, 40 Bernard Street, London, WC1N 1ST
collaborator UNKNOWN -
Loughborough University
lead OTHER
Principal Investigators
-
Ronald Maughan, PhD · Loughborough University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 35 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-03-31
- Primary Completion
- 2006-09-30
- Completion
- 2006-09-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Beclomethasone in Healthy Athletes
NCT05352191 ·Status: UNKNOWN ·Phase: PHASE4
-
Reproducibility of Acute Caffeine Effect
NCT06606639 ·Status: COMPLETED ·Phase: NA
-
Response to Clenbuterol in Humans
NCT03860870 ·Status: COMPLETED ·Phase: NA
-
Synthetic THC And Blood Pressure
NCT07231965 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Drug Use and Ultra-endurance Race
NCT03402022 ·Status: COMPLETED
-
Can Anti-asthmatic Medication Improve Sprint Performance in Healthy Endurance Athletes?
NCT04402658 ·Status: WITHDRAWN ·Phase: NA
-
Pharmacokinetics and Pharmacological Effects of a Standardized Cannabis Preparation
NCT04841993 ·Status: COMPLETED ·Phase: PHASE1
-
L-Citrulline and Endothelial Function
NCT05722860 ·Status: COMPLETED ·Phase: PHASE1
-
Terbutaline Concentrations in Blood and Urine
NCT00914797 ·Status: UNKNOWN ·Phase: PHASE4
-
Testosterone and Neurovascular Control in Humans
NCT04819204 ·Status: UNKNOWN ·Phase: NA
-
Hydration and Exercise Performance in Cycling
NCT03304197 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetic Effects of Oral DMAA
NCT01765933 ·Status: COMPLETED ·Phase: NA
-
The Effects of Caffeine on Pain-Based Pacing During a Cycling Time-Trial
NCT02115763 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacological Properties of Salmeterol
NCT02558088 ·Status: COMPLETED ·Phase: PHASE4
-
Caffeine and Resistance Training in Older Adults
NCT06618261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Cannabidiol Effects on Cardiovascular System and Exercise Responses
NCT05232123 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Multi-level Molecular Profiling of Stress Exposure Under Standardized Food Intake: A Clinical Study
NCT06016530 ·Status: UNKNOWN ·Phase: NA
-
Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping
NCT03548766 ·Status: UNKNOWN ·Phase: PHASE3
-
Method Optimization for the Quantification of the NAD
NCT05561712 ·Status: COMPLETED
-
Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints
NCT05846451 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions
NCT01448772 ·Status: COMPLETED ·Phase: PHASE1
-
Caffeine, Resistance Exercise and Muscle/Cerebral Oxygenation
NCT07001176 ·Status: COMPLETED ·Phase: NA
-
Healthy Aging Through Dietary Intervention
NCT05782309 ·Status: COMPLETED ·Phase: NA
-
Determination of Drugs and Their Metabolites in Hospitalized Patients
NCT01702545 ·Status: UNKNOWN
-
Oslo Antioxidant Study
NCT00520819 ·Status: COMPLETED ·Phase: PHASE1/PHASE2